Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.), Galderma Laboratories, L.P. and Mylan N.V. are Dominating the Asia-Pacific Dermatology Drugs Market in 2019

Asia-Pacific Dermatology Drugs Market is expected to grow with the CAGR of 10.5% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access full Report @ https://www.databridgemarketresearch.com/reports/asia-pacific-dermatology-drugs-market

Asia-Pacific dermatology drugs market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.  

The major players dealing in Asia-Pacific dermatology drugs market are introducing strong range of products provider along with receiving large number of CE mark approvals for launching new products into the market. For instance,

  • In October 2019, Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.) announced that they have received approval from the U.S. Food and Drug Administration’s (FDA) for their product Stelara, which is used in the treatment of adult patients suffering from slightly to severely active ulcerative colitis. The new product is going to help the company in expanding its profit along with revenue for the company.

Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.)., is the dominating player in dermatology drugs market. The other key players existing in the market includes are Novartis AG, Pfizer Inc., Eli Lilly and Company., Almirall, S.A, Mylan N.V., Sun Pharmaceutical Industries Ltd., UCB S.A., Belgium, Glenmark Pharmaceuticals Limited, GlaxoSmithKline plc., Galderma Laboratories, L.P., Teva Pharmaceutical Industries Ltd., LEO Pharma A/S, Mayne Pharma Group Limited, AbbVie Inc., Cipla Inc, Vibcare Pharma Pvt. Ltd, Ciaga among others. 

Asia-Pacific Dermatology Drugs MarketJanssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.)

 Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.) is engaged in the research and development, manufacturing and sale of a wide range of products in the health care field. The company has multiple business segments pharmaceutical, medical devices, and consumer. The company also has wide product portfolio such as cardiovascular and metabolism, immunology, infectious diseases and vaccines, neuroscience, oncology, pulmonary hypertension and immunology is the market focused category.  The company also has global presence in Asia-Pacific, Europe, Middle East and Africa and Americas.

For instance:

  • In April 2020, The Janssen pharmaceutical companies of Johnson & Johnson Services, INC. announced that it has submitted Biologics License Applications (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA.

Galderma Laboratories, L.P.

Galderma Laboratories, L.P, headquartered in Texas, U.S. which was founded in 1981. The company offers a range of leading medical and consumer skin health brands, through three strategic areas: prescription, aesthetics, and consumer. The company also has several brand categories including prescription and aesthetics (Epiduo Forte, Mirvaso, Dysport, Sculptra, Oracea, Soolantra, Restylane, Aklife), consumer solutions (Differin, Proactiv, Cetaphi. The company has presence in Asia-Pacific, Europe, Middle East and Africa, and Americas.

For instance:

  • In October 2019, Galderma Laboratories, L.P. announced that they have received approvals from FDA regarding Aklief (trifarotene) cream which is a topical cream to treat acne. This has widened their products profile and also led to increased revenue generation.

Mylan N.V.

Mylan N.V., headquartered in Pennsylvania, U.S. which was founded in 1961. The company is engaged in development and manufacturing of the generic and specialty pharmaceuticals for the treatment of various disorders such as respiratory, neurology and allergy. The company also has wide product portfolio in biosimilars, generics, brand, over-the-counter, and API. The company has presence in Americas, Europe, Middle East and Africa, and Asia-Pacific. The company also has various subsidiary companies such as Meda AB (Sweden), Generics (UK) Ltd (U.K.), Alphapharm (Australia), McDermott Laboratories Ltd (Ireland) and DPT Laboratories (U.S.) among others.

For instance:

  • In August 2016, Mylan N.V. completely acquired the company Meda. The acquisition has added the unmatched platform of research and development and manufacturing into Mylan N.V. This acquisition has broadened the resources and made Mylan N.V. a more powerful global commercial infrastructure across the developed and flourished markets which made branded, generic and over-the-counter products. This transition has great hike in the sales in future